Equities research analysts predict that Pluristem Therapeutics Inc. (NASDAQ:PSTI) will announce earnings of ($0.70) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Pluristem Therapeutics’ earnings. Pluristem Therapeutics reported earnings per share of ($0.90) during the same quarter last year, which suggests a positive year-over-year growth rate of 22.2%. The company is scheduled to report its next quarterly earnings report on Thursday, September 26th.
According to Zacks, analysts expect that Pluristem Therapeutics will report full-year earnings of ($3.05) per share for the current financial year, with EPS estimates ranging from ($3.10) to ($3.00). For the next year, analysts expect that the business will post earnings of ($2.60) per share, with EPS estimates ranging from ($2.90) to ($2.30). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Pluristem Therapeutics.
PSTI has been the topic of several research reports. ValuEngine cut shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded shares of Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 10th. Finally, LADENBURG THALM/SH SH assumed coverage on shares of Pluristem Therapeutics in a research report on Monday, July 22nd. They set a “buy” rating on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Pluristem Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $27.50.
Large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC grew its position in Pluristem Therapeutics by 266.1% during the 1st quarter. Virtu Financial LLC now owns 85,104 shares of the biotechnology company’s stock valued at $83,000 after purchasing an additional 61,858 shares during the last quarter. United Capital Financial Advisers LLC raised its stake in shares of Pluristem Therapeutics by 37.8% during the second quarter. United Capital Financial Advisers LLC now owns 85,733 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 23,533 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Pluristem Therapeutics by 28.1% during the second quarter. Jane Street Group LLC now owns 153,322 shares of the biotechnology company’s stock valued at $95,000 after acquiring an additional 33,630 shares during the last quarter. Verition Fund Management LLC acquired a new stake in shares of Pluristem Therapeutics during the second quarter worth $231,000. Finally, Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of Pluristem Therapeutics during the first quarter worth $881,000. Institutional investors and hedge funds own 6.00% of the company’s stock.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
See Also: Dividend Yield
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.